Journey Medical Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

INTANGIBLE ASSETS

INTANGIBLE ASSETS

6 Months Ended

Jun. 30, 2026

NOTE 5. INTANGIBLE ASSETS

The Company’s finite-lived intangible assets consist of acquired intangible assets. The Company’s intangible assets as of June 30, 2026 and December 31, 2025 are summarized as follows:


	Estimated
	Useful Lives			June 30,			December 31,
($’s in thousands)	(Years)			2026			2025
Intangible assets - product licenses		3-15		$	52,925		$	52,925
Accumulated amortization					(24,272)			(22,177)
Accumulated impairment loss					(3,143)			(3,143)
Total intangible assets				$	25,510		$	27,605

The Company’s amortization expense for the three-month periods ended June 30, 2026 and 2025 was $1.0 million and $1.1 million, respectively. The Company’s amortization expense for the six-month periods ended June 30, 2026 and 2025 was $2.1 million and $2.1 million, respectively.

In December 2025, the Company received FDA approval for Eurax®, formerly known as the anti-itch product, which was acquired in 2020. Prior to FDA approval, Eurax had been presented as an intangible asset not yet placed in service totaling $3.9 million. The Company began amortizing the Eurax intangible asset in January 2026.

Future amortization of the Company’s intangible assets is as follows:


For the years ended	Total Amortization
Remainder of 2026	$	1,938
December 31, 2027		3,338
December 31, 2028		3,159
December 31, 2029		3,159
December 31, 2030		3,159
Thereafter		10,757
Total	$	25,510